Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Renalys Aims to File Sparsentan for IgA Nephropathy in Japan in 2026
April 19, 2024
- Fujifilm Shoots for 700 Billion Yen in Bio-CDMO Sales by FY2030
April 18, 2024
- Voydeya, High-Dose Eylea, Vyvdura and More Now Available in Japan
April 18, 2024
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- Santen’s New China Plant Completed, Poised for 2027 Launch
April 17, 2024
- Jardiance, Ofev Continue to Drive Boehringer’s Global Sales
April 17, 2024
- Nippon Shinyaku Seeks Uptravi Use in Pediatric PAH in Japan
April 17, 2024
- Lagevrio’s Smaller Tablet Version Filed in Japan: MSD
April 17, 2024
- Moderna to File mRNA RSV Vaccine in Japan within 2024: Exec
April 17, 2024
- 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey
April 16, 2024
- Meiji Reaffirms 2028 Launch Plan for New Vaccine Site as METI Grants Finalized
April 16, 2024
- Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
- Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success
April 16, 2024
- Xofluza Approved for Pediatric Use in Taiwan: Shionogi
April 16, 2024
- Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
- Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
- Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
- MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
- Wholesaler Purchase Prices of Unprofitable Drugs on Upward Trend after FY2024 Revision
April 12, 2024
- Japan Autoimmune Drug Market Likely to Top 1 Trillion Yen in 2033: Fuji Keizai
April 12, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…